Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use

Michael H. Hoskins, Rebecca M. Leleiko, Julie J. Ramos, Srikanth Sola, Patrick M. Caneer, Bobby V. Khan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P <.005) and 16% in IL-6 (P <.005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P <.005 time and group comparison), 22% in IL-6 (P <.005 time and group comparison), and 18% in choline (P <.005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.

Original languageEnglish (US)
Pages (from-to)47-52
Number of pages6
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume15
Issue number1
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Labetalol
Acute Coronary Syndrome
Cocaine
Diltiazem
Biomarkers
Hemodynamics
Inflammation
CD40 Ligand
Interleukin-6
Choline
Serum
Blood Vessels
Hospitalization
Anti-Inflammatory Agents
Heart Rate
Urine
Blood Pressure
Safety
Mortality
Therapeutics

Keywords

  • β-blocker
  • Acute coronary syndrome
  • Cocaine
  • Ischemia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. / Hoskins, Michael H.; Leleiko, Rebecca M.; Ramos, Julie J.; Sola, Srikanth; Caneer, Patrick M.; Khan, Bobby V.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 15, No. 1, 03.2010, p. 47-52.

Research output: Contribution to journalArticle

Hoskins, Michael H. ; Leleiko, Rebecca M. ; Ramos, Julie J. ; Sola, Srikanth ; Caneer, Patrick M. ; Khan, Bobby V. / Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2010 ; Vol. 15, No. 1. pp. 47-52.
@article{fdc2844b0ae94ab99bbcd59c8fe1d34c,
title = "Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use",
abstract = "Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17{\%} in CD40 ligand (P <.005) and 16{\%} in IL-6 (P <.005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30{\%} in CD40 ligand (P <.005 time and group comparison), 22{\%} in IL-6 (P <.005 time and group comparison), and 18{\%} in choline (P <.005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.",
keywords = "β-blocker, Acute coronary syndrome, Cocaine, Ischemia",
author = "Hoskins, {Michael H.} and Leleiko, {Rebecca M.} and Ramos, {Julie J.} and Srikanth Sola and Caneer, {Patrick M.} and Khan, {Bobby V.}",
year = "2010",
month = "3",
doi = "10.1177/1074248409358409",
language = "English (US)",
volume = "15",
pages = "47--52",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use

AU - Hoskins, Michael H.

AU - Leleiko, Rebecca M.

AU - Ramos, Julie J.

AU - Sola, Srikanth

AU - Caneer, Patrick M.

AU - Khan, Bobby V.

PY - 2010/3

Y1 - 2010/3

N2 - Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P <.005) and 16% in IL-6 (P <.005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P <.005 time and group comparison), 22% in IL-6 (P <.005 time and group comparison), and 18% in choline (P <.005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.

AB - Cocaine use is associated with increased cardiovascular mortality and can promote acute coronary syndrome (ACS). Use of β-blockers is controversial in patients who use cocaine, and the safety and efficacy of these medications in ACS in patients actively using cocaine is unknown. We enrolled 90 patients with ACS and positive urine drug screen for cocaine. Patients received standard ACS therapy plus either labetalol (n = 60) or diltiazem (n = 30). Blood pressure and heart rate were measured at baseline and 48 hours. Levels of serum CD40 ligand, interleukin (IL)-6, and choline at baseline and 48 hours were determined. There were no baseline differences in hemodynamics or serum levels of inflammatory markers between the labetalol and diltiazem groups. Both groups experienced a significant and equivalent decrease in BP and HR at 48 hours compared with baseline. At 48 hours of treatment, there were significant decreases of 17% in CD40 ligand (P <.005) and 16% in IL-6 (P <.005) but no change in choline in the diltiazem group. Furthermore, in the labetalol group, there were significant differences of 30% in CD40 ligand (P <.005 time and group comparison), 22% in IL-6 (P <.005 time and group comparison), and 18% in choline (P <.005 time and group comparison). There were no adverse events during hospitalization in any patients who received labetalol. In conclusion, labetalol appears to be safe in cocaine-associated ACS. Furthermore, labetalol provides a beneficial hemodynamic response and, in comparison to diltiazem, potentiates an anti-inflammatory vascular response in this setting.

KW - β-blocker

KW - Acute coronary syndrome

KW - Cocaine

KW - Ischemia

UR - http://www.scopus.com/inward/record.url?scp=76649121168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649121168&partnerID=8YFLogxK

U2 - 10.1177/1074248409358409

DO - 10.1177/1074248409358409

M3 - Article

C2 - 20133495

AN - SCOPUS:76649121168

VL - 15

SP - 47

EP - 52

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 1

ER -